Niagen Bioscience (NASDAQ:NAGE) Reaches New 1-Year High - What's Next?

Niagen Bioscience, Inc. (NASDAQ:NAGE - Get Free Report) shares reached a new 52-week high during mid-day trading on Monday . The company traded as high as $14.69 and last traded at $14.04, with a volume of 192730 shares changing hands. The stock had previously closed at $14.22.

Analysts Set New Price Targets

NAGE has been the topic of a number of recent research reports. Roth Capital reissued a "buy" rating and set a $23.00 target price (up from $10.00) on shares of Niagen Bioscience in a research report on Friday, June 6th. Wall Street Zen raised shares of Niagen Bioscience from a "buy" rating to a "strong-buy" rating in a research note on Sunday, June 22nd. Finally, Canaccord Genuity Group boosted their price objective on shares of Niagen Bioscience from $13.00 to $16.00 and gave the stock a "buy" rating in a report on Tuesday, June 10th.

Niagen Bioscience Stock Performance

The firm has a fifty day simple moving average of $10.81 and a 200-day simple moving average of $7.62. The company has a market capitalization of $1.12 billion, a PE ratio of 83.59 and a beta of 2.08.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.